Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

XPhyto Therapeutics Corp., CA98421R1055

XPhyto Therapeutics Corp., CA98421R1055

25.11.2019 - 19:16:17

XPhyto Therapeutics Pharmaceutical-Grade Cannabis Extraction Lab

DGAP-News: XPhyto Therapeutics Corp.

/ Key word(s): Miscellaneous

XPhyto Therapeutics Pharmaceutical-Grade Cannabis Extraction Lab

25.11.2019 / 19:14

The issuer is solely responsible for the content of this announcement.

For further information, please contact:

Hugh RogersCEO & Director

+1.780.818.6422info@xphyto.comwww.xphyto.com

Robert BarthVP European Corporate Development+49 8331 99481 10info@xphyto.comwww.xphyto.com

Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50069

Click on, or paste the following link into your web browser,to view the associated documents

http://www.newsfilecorp.com/release/50069 News Source: Newsfile

25.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: XPhyto Therapeutics Corp.

Canada ISIN: CA98421R1055 EQS News ID: 921411   End of News DGAP News Service

921411  25.11.2019 

@ dgap.de